Erratum: Department of Error(S0140673613602500)(10.1016/S0140-6736(13)60250-0);Tocilizumab monotherapy versus adalimumab monotherapy for treatment of rheumatoid arthritis (ADACTA): A randomised, double-blind, controlled phase 4 trial

The Lancet

Volumn 381, Issue 9877, 2013, Pages 1541-1550

  Gabay, Cem ^a   Emery, Paul ^b   Van Vollenhoven, Ronald ^c   Dikranian, Ara ^d   Alten, Rieke ^e   Pavelka, Karel ^f   Klearman, Micki ^g   Musselman, David ^g   Agarwal, Sunil ^g   Green, Jennifer ^h   Kavanaugh, Arthur ⁱ  

^a GENEVA UNIVERSITY HOSPITALS   (Switzerland)

^b UNIVERSITY OF LEEDS   (United Kingdom)

^c KAROLINSKA INSTITUTE   (Sweden)

^d San Diego Arthritis Medical Clinic   (United States)

^e HUMBOLDT UNIVERSITY   (Germany)

^f NATIONAL INSTITUTE OF RHEUMATIC DISEASES   (Slovakia)

^g GENENTECH INC   (United States)

^h ROCHE PRODUCTS LTD   (United Kingdom)

ⁱ UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; ALANINE AMINOTRANSFERASE; LOW DENSITY LIPOPROTEIN CHOLESTEROL; METHOTREXATE; PLACEBO; TOCILIZUMAB;

ABSCESS; ADULT; APPENDIX PERFORATION; ARTICLE; AUSTRALIA AND NEW ZEALAND; BRONCHITIS; CELLULITIS; CONTROLLED STUDY; DISEASE ACTIVITY SCORE; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; EUROPE; FEMALE; HEMATOMA; HUMAN; INFECTION; INTENTION TO TREAT ANALYSIS; LABYRINTHITIS; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; NEUTROPHIL COUNT; PARALLEL DESIGN; PAROTITIS; PHASE 4 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RHEUMATOID ARTHRITIS; SINUSITIS; SOUTH AMERICA; TENOSYNOVITIS; THROMBOCYTE COUNT; URINARY TRACT INFECTION; UROSEPSIS; VESTIBULAR NEURONITIS;

EID: 84877275257     PISSN: 01406736     EISSN: 1474547X     Source Type: Journal    
DOI: 10.1016/S0140-6736(13)62626-4     Document Type: Erratum

References (39)

1. C Salliot, D Van Der Heijde Long term safety of methotrexate monotherapy in rheumatoid arthritis patients: a systematic literature research Ann Rheum Dis 68 2009 1100 1104
2. CT Goudie, JD Fitzpatrick, AP Malaviya, AJ Ostor How well do patients with rheumatoid and psoriatic arthritis tolerate methotrexate? A retrospective review of discontinuation data from a large UK cohort Arthritis Rheum 64 10 suppl 2012 S560 abstr 1306.
3. GW Cannon, TR Mikuls, CL Hayden et al. Merging Veterans Affairs rheumatoid arthritis registry and pharmacy data to assess methotrexate adherence and disease activity in clinical practice Arthritis Care Res 63 2011 1680 1690
4. A de Thurah, M Norgaard, I Harder, K Stengaard-Pedersen Compliance with methotrexate treatment in patients with rheumatoid arthritis: influence of patients' beliefs about the medicine: a prospective cohort study Rheumatol Int 30 2010 1441 1448
5. CG Grijalva, L Kaltenbach, PG Arbogast, EF Mitchel Jr, MR Griffin Adherence to disease-modifying antirheumatic drugs and the effects of exposure misclassification on the risk of hospital admission Arthritis Care Res 62 2010 730 734
6. MS Heiberg, W Koldingsnes, K Mikkelsen et al. The comparative one-year performance of anti-tumor necrosis factor alpha drugs in patients with rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis: results from a longitudinal, observational, multicenter study Arthritis Rheum 59 2008 234 240 (Pubitemid 351272960)
7. MM Soliman, DM Ashcroft, KD Watson et al. Impact of concomitant use of DMARDs on the persistence with anti-TNF therapies in patients with rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register Ann Rheum Dis 70 2011 583 589
8. J Listing, A Strangfeld, R Rau et al. Clinical and functional remission: even though biologics are superior to conventional DMARDs overall success rates remain low - results from RABBIT, the German biologics register Arthritis Res Ther 8 2006 R66
9. J Askling, CM Fored, L Brandt et al. Time-dependent increase in risk of hospitalisation with infection among Swedish RA patients treated with TNF antagonists Ann Rheum Dis 66 2007 1339 1344 (Pubitemid 47492478)
10. X Mariette, JE Gottenberg, P Ravaud, B Combe Registries in rheumatoid arthritis and autoimmune diseases: data from the French registries Rheumatology 50 2011 222 229
11. SJ Lee, H Chang, Y Yazici et al. Utilization trends of tumor necrosis factor inhibitors among patients with rheumatoid arthritis in a United States observational cohort study J Rheumatol 36 2009 1611 1617
12. Y Yazici, N Shi, A John Utilization of biologic agents in rheumatoid arthritis in the United States: analysis of prescribing patterns in 16,752 newly diagnosed patients and patients new to biologic therapy Bull NYU Hosp Joint Dis 66 2008 77 85 (Pubitemid 351898370)
13. JM Dayer, E Choy Therapeutic targets in rheumatoid arthritis: the interleukin-6 receptor Rheumatology 49 2010 15 24
14. JE Gottenberg, JM Dayer, C Lukas et al. Serum IL-6 and IL-21 are associated with markers of B cell activation and structural progression in early rheumatoid arthritis: results from the ESPOIR cohort Ann Rheum Dis 71 2012 1243 1248
15. PP Tak, TJ Smeets, MR Daha et al. Analysis of the synovial cell infiltrate in early rheumatoid synovial tissue in relation to local disease activity Arthritis Rheum 40 1997 217 225 (Pubitemid 27114085)
16. M Mihara, K Kasutani, M Okazaki et al. Tocilizumab inhibits signal transduction mediated by both mIL-6R and sIL-6R, but not by the receptors of other members of IL-6 cytokine family Int Immunopharmacol 5 2005 1731 1740 (Pubitemid 41116745)
17. N Nishimoto, T Kishimoto Humanized antihuman IL-6 receptor antibody, tocilizumab Handb Exp Pharmacol 181 2008 151 160
18. P Emery, E Keystone, HP Tony et al. IL-6 receptor inhibition with tocilizumab improves treatment outcomes in patients with rheumatoid arthritis refractory to anti-tumour necrosis factor biologicals: results from a 24-week multicentre randomised placebo-controlled trial Ann Rheum Dis 67 2008 1516 1523
19. JS Smolen, A Beaulieu, A Rubbert-Roth et al. Effect of interleukin-6 receptor inhibition with tocilizumab in patients with rheumatoid arthritis (OPTION study): a double-blind, placebo-controlled, randomised trial Lancet 371 2008 987 997 (Pubitemid 351392039)
20. MC Genovese, JD McKay, EL Nasonov et al. Interleukin-6 receptor inhibition with tocilizumab reduces disease activity in rheumatoid arthritis with inadequate response to disease-modifying antirheumatic drugs: the tocilizumab in combination with traditional disease-modifying antirheumatic drug therapy study Arthritis Rheum 58 2008 2968 2980
21. JM Kremer, R Blanco, S Brzosko et al. Tocilizumab inhibits structural joint damage in rheumatoid arthritis patients with inadequate responses to methotrexate: results from the double-blind treatment phase of a randomised placebo-controlled trial of tocilizumab safety and prevention of structural joint damage at one year Arthritis Rheum 63 2011 609 621
22. G Jones, A Sebba, J Gu et al. Comparison of tocilizumab monotherapy versus methotrexate monotherapy in patients with moderate to severe rheumatoid arthritis: the AMBITION study Ann Rheum Dis 69 2010 88 96
23. N Nishimoto, J Hashimoto, N Miyasaka et al. Study of active controlled monotherapy used for rheumatoid arthritis, an IL-6 inhibitor (SAMURAI): evidence of clinical and radiographic benefit from an x ray reader-blinded randomised controlled trial of tocilizumab Ann Rheum Dis 66 2007 1162 1167 (Pubitemid 47309731)
24. N Nishimoto, N Miyasaka, K Yamamoto et al. Study of active controlled tocilizumab monotherapy for rheumatoid arthritis patients with an inadequate response to methotrexate (SATORI): significant reduction in disease activity and serum vascular endothelial growth factor by IL-6 receptor inhibition therapy Mod Rheumatol 19 2009 12 19
25. E Weinblatt, JM Kremer, JJ Cush et al. Tocilizumab monotherapy and tocilizumab plus disease-modifying antirheumatic drugs in a US rheumatoid arthritis population with inadequate response to anti-tumor necrosis factor agents Arthritis Rheum 63 2011 S162
26. M Dougados, K Kissel, T Sheeran et al. Adding tocilizumab or switching to tocilizumab monotherapy in methotrexate inadequate responders: 24-week symptomatic and structural results of a 2-year randomised controlled strategy trial in rheumatoid arthritis (ACT-RAY) Ann Rheum Dis 72 2013 43 50
27. ML Prevoo, MA van't Hof, HH Kuper, MA van Leeuwen, LB van de Putte, PL van Riel Modified disease activity scores that include twenty-eight-joint counts: development and validation in a prospective longitudinal study of patients with rheumatoid arthritis Arthritis Rheum 38 1995 44 48
28. DT Felson, JJ Anderson, M Boers et al. American College of Rheumatology: preliminary definition of improvement in rheumatoid arthritis Arthritis Rheum 38 1995 727 735
29. PL van Riel, AM van Gestel, LB van de Putte Development and validation of response criteria in rheumatoid arthritis: steps towards an international consensus on prognostic markers Br J Rheumatol 35 suppl 2 1996 4 7
30. JF Fries, PW Spitz, DY Young The dimensions of health outcomes: the Health Assessment Questionnaire, disability and pain scales J Rheumatol 9 1982 789 793
31. JF Fries, PW Spitz, RG Kraines, HR Holman Measurement of patient outcome in arthritis Arthritis Rheum 23 1980 137 145 (Pubitemid 10164318)
32. DT Felson, JS Smolen, G Wells et al. American College of Rheumatology/European League Against Rheumatism provisional definition of remission in rheumatoid arthritis for clinical trials Ann Rheum Dis 70 2011 404 413
33. D Cella, S Yount, M Sorensen, E Chartash, N Senqupta, J Grober Validation of the Functional Assessment of Chronic Illness Therapy Fatigue Scale relative to other instrumentation in patients with rheumatoid arthritis J Rheumatol 32 2005 811 819 (Pubitemid 40676488)
34. JE Ware Jr, CD Sherbourne The MOS 36-Item Short-Form Health Survey (SF-36): I: conceptual framework and item selection Med Care 30 1992 473 483
35. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults Executive summary of the third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) JAMA 2815 2001 2486 2497
36. LBA Van de Putte, C Atkins, M Malaise et al. Efficacy and safety of adalimumab as monotherapy in patients with rheumatoid arthritis for whom previous disease modifying antirheumatic drug treatment has failed Ann Rheum Dis 63 2004 508 516 (Pubitemid 38530193)
37. Humira 40 mg solution for injection (summary of product characteristics) 2010 Abbott Laboratories Berkshire, UK
38. RoActemra® (tocilizumab) (summary of product characteristics) Welwyn Garden City 2011 Roche UK
39. R Fleischmann, M Cutolo, MC Genovese et al. Phase IIb dose-ranging study of the oral JAK inhibitor tofacitinib (CP-690,550) or adalimumab monotherapy versus placebo in patients with active rheumatoid arthritis with an inadequate response to disease-modifying antirheumatic drugs Arthritis Rheum 64 2012 617 629